Table 1.
Summary of prospective studies reporting on bedaquiline‐containing treatment for MDR‐TB patients
| Corresponding author, countries, publication year | No. of cases in efficacy assessment/no. of cases in the study | No. (%) pre‐XDR‐TB cases | No. (%) XDR‐TB cases | Regimen design | No. (%) of cases taking LZD | No. (%) cases HIV‐infected | The median time to culture conversion (days) | Sputum culture conversion at week 24 | Treatment outcome evaluation |
|---|---|---|---|---|---|---|---|---|---|
| Andreas H. Diacon, South Africa, 2012 | 21/23 | 2 (8.7%) | 0 (0%) | A background regimen plus 8‐week BDQ or placebo. | 0 (0%) | 3 (13%) | 78 | 17/21 (81%) | 11 (51%) had favorable outcome. |
| Brian Dannemann, multi‐countrya, 2014 | 66/80 | 15 (28%) | 0 (0%) | A background regimen plus 24‐week BDQ or placebo. | 0 (0%) | 5 (8%) | 83 | 52/66 (79%) | 38 (58%) had favorable outcome. |
| Alexander S. Pym1, multi‐countryb, 2017 | 205/233 | 44 (21%) | 37 (18%) | A background regimen plus 24‐week BDQ. | 34 (14%) | 0 (0%) | 57 | 163/205 (79%) | 128 (62%) had favorable outcome. |
| Norbert Ndjeka, South Korea, 2015 | 41/91 | 41 (45%) | 33 (36%) | An optimized regimen of at least three drugs plus BDQ for 24 weeks. | 63 (69%) | 54 (59%) | 45 | 33/48 (69%) | Not specified. Only early efficacy assessment. |
| Keertan Dheda, South Africa, 2018 | 68/272 | 0 (0%) | 272 (100%) | A DST‐individualized regimen of a median of five effective drugs. | 55 (81%) | 35 (51%) | Not specified | 46/68 (68%) | 45 (66%) had favorable outcome. |
MDR‐TB = multidrug‐resistant tuberculosis; pre‐XDR‐TB = pre‐extensively drug‐resistant tuberculosis; XDR‐TB = extensively drug‐resistant tuberculosis; LZD = linezolid; BDQ = bedaquiline; DST = Drug susceptibility testing.
a
This study enrolled patients from eight countries in Brazil, India, Latvia, Peru, the Philippines, Russia, South Africa, and Thailand.
b
This study enrolled patients from 11 countries in China, South Korea, Estonia, Latvia, Turkey, Ukraine, Peru, the Philippines, Russia, South Africa, and Thailand.